EUVIMED · CrossrefJournal
Urologic Oncology: Seminars and Original Investigations
ISSN 1078-1439 · Elsevier BV
Latest articles
Clinical characteristics and oncological outcomes of upper tract urothelial carcinoma in patients with personal or family history of Lynch-syndrome-associated cancers
Is all gross hematuria high risk? Age-stratified outcomes after anticoagulation initiation using a large claims database
PCOLCE2 inhibits BLCA progression via ACSL6-dependent ferroptosis and its transcription is suppressed by the BDH1-H3K9bhb axis
The added value of systematic biopsy in the MRI-targeted prostate biopsy era: Correlation with radical prostatectomy findings
Retraction notice to “Opium Consumption and Risk of Bladder Cancer: A Case-Control Analysis” Urologic Oncology: Seminars and Original Investigations 28 (2010) 610–616
Retraction notice to “Combination Chemotherapy with Docetaxel, Estramustine and Suramin for Hormone Refractory Prostate Cancer” [Urologic Oncology: Seminars and Original Investigations 23 (2005) 93–101]
Retraction notice to “Safety and Efficacy Of Sorafenib In Patients With Castrate Resistant Prostate Cancer: A Phase II Study” [Urologic Oncology: Seminars and Original Investigations 28 (2010) 21–27]
Nonsurgical UGN-102 for recurrent LG-IR-NMIBC: Pooled efficacy and safety from phase 2 and 3 trials
Comparison of novel salvage therapies for BCG-unresponsive NMIBC against gemcitabine/docetaxel: A reconstructed individual patient data analysis
Adoption and perceptions of utility of the RENAL nephrometry score among fellowship-trained urologic oncologists in North America
Molecular profiling of renal mass biopsy tissue: A review of feasibility and clinical utility
Adherence to active surveillance monitoring among Medicare beneficiaries with prostate cancer
The role of lymph node dissection in upper tract urothelial carcinoma
Liver transplant team involvement in level III and IV renal tumor thrombectomy: Perioperative and oncologic outcomes
Nanoparticle delivery of phytochemicals and dietary factors for epigenetic modulation in prostate cancer
FOXP2/FABP4 axis promotes bladder cancer aggressiveness by driving lipid metabolic reprogramming to activate FAK/Src signaling
PARP inhibitor–based combinations in first-line metastatic castration-resistant prostate cancer: A meta-analysis
Impact of obesity with metabolic comorbidities on oncologic outcomes in patients with upper tract urothelial carcinoma
Prognostic utility of preoperative NLR, PLR, SII in penile cancer: A National Cohort Study
Beyond KEYNOTE-564 eligibility: A clinical decision aid to refine selection for adjuvant pembrolizumab in clear cell renal cell carcinoma
Comment on “Cryoablation for localized prostate cancer: Feasibility in large prostates”
Re: Development and validation of a computational histology artificial intelligence-powered prognostic biomarker in muscle-invasive bladder cancer
Editorial commentary
Cover 2 - Masthead
Editorial Board
Table of Contents
Quantitative core-level tumor burden and grading in MRI-targeted vs. systematic prostate biopsy: A within-patient paired analysis
Cell-surface targets for prostate cancer therapeutics
Re: Etiology of testosterone deficiency after radical prostatectomy
Neoadjuvant, adjuvant, and perioperative therapy comparisons in muscle-invasive bladder cancer: Clinical and methodological considerations for the interpretation of network meta-analytic findings
Volumes
2026 · 4102025 · 6272024 · 5222023 · 3062022 · 3402021 · 3762020 · 3542019 · 2702018 · 3102017 · 3742016 · 2922015 · 3232014 · 3632013 · 3352012 · 2442011 · 2032010 · 1652009 · 2592008 · 2202007 · 2002006 · 1862005 · 1792004 · 2282003 · 1712002 · 582001 · 582000 · 601998 · 321997 · 341996 · 461995 · 51
EUVIMED